In the 3rd quarter, we recorded GAAP net income of $12,000,000 which when adjusted for non GAAP items results in non GAAP net income of $15,000,000 This compares to GAAP net income of $2,000,000 in the prior year quarter and non GAAP net income of 4,000,000 dollars For the 9 month period of 2024, we reported net income of $20,000,000 and non GAAP net income of $45,000,000 whereas for the same period in 2023, we reported a net loss of 13,000,000 and a non GAAP net loss of $1,000,000 As we highlighted earlier on the call, last year we transitioned to running the endocrine business unit for profitability, which has contributed approximately $11,000,000 year to date in operating income. This combined with our net royalty income and the margin earned from collaboration and services has allowed us to fund our 2 promising development programs to date and also achieve net income of $20,000,000 for the year to date period and $45,000,000 non GAAP. The operational execution of our business combined with our cash and investments of $268,000,000 as of the end of September leaves us with a strong balance sheet and the ability to invest in the business for growth.